Human engineered enzymes for L-Arg depletion chemotherapy

用于 L-Arg 耗竭化疗的人类工程酶

基本信息

批准号：
8039233
负责人：
GEORGE Georgiou GEORGIOU
金额：
$ 33.06万
依托单位：
UNIVERSITY OF TEXAS AT AUSTIN
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-03-01 至 2013-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8039233
关键词：
Acute Lymphocytic Leukemia Adverse effects Alteplase Amino Acid Substitution Amino Acids Anabolism Animal Model Antibodies Arginine Arginine deiminase Asparagine Bacterial Proteins Bacteriophages Binding Biochemical Bioinformatics Blood Vessels Carbamoyl Transferases Carcinoma Cell Death Cell Line Cessation of life Chimeric Proteins Citrulline Clinical Clinical Data Clinical Trials Combined Modality Therapy Development Disease Dose Drug Kinetics Effectiveness Engineering Enzyme Kinetics Enzyme Stability Enzymes Epitopes Essential Amino Acids Europe Evaluation Exhibits FDA approved Fc domain Generations Goals Growth Half-Life Health Human Human Development Human Engineering Human Genome Immune Immune response Immune system Immunoglobulin G Immunoglobulins In Vitro Injection of therapeutic agent International Isoenzymes Italy Kinetics Laboratories Lead Life Malignant Epithelial Cell Malignant Neoplasms Malignant neoplasm of liver Measures Mediating Metabolic Methionine Modification Mucopolysaccharidosis I Mus Mutagenesis Mutation Non-Essential Amino Acid Non-Hodgkin&apos s Lymphoma Normal Cell Normal tissue morphology Nude Mice Ornithine Ornithine Carbamoyltransferase Orphan Drugs Pathway interactions Patients Pegaspargase Pharmacodynamics Phase Physiological Plasma Polymers Primary carcinoma of the liver cells Property Protein Engineering Protein-arginine deiminase Proteins Reaction Recycling Renal Cell Carcinoma Research Serum Specificity Structure Substrate Specificity Techniques Testing Therapeutic Therapeutic Agents Translating Treatment Efficacy Variant Work Xenograft procedure arginase argininosuccinate synthase asparaginase bioprocess cancer cell cancer therapy catalyst cell growth cell killing chemotherapy clinical practice cofactor combinatorial coping cytotoxic cytotoxicity design efficacy evaluation experience high throughput screening immunogenic immunogenicity improved in vivo killings loved ones melanoma mouse model mutant novel strategies particle polypeptide pre-clinical research clinical testing therapeutic protein tissue culture treatment strategy tumor

项目摘要

DESCRIPTION (provided by applicant): The overall objective of this proposal is to employ modern techniques of protein engineering to develop a new generation of non-immunogenic and pharmacologically optimized enzyme for chemotherapy of hepatic cancers and melanomas by systemic L-Arginine depletion. Enzymatic depletion of arginine using PEGylated bacterial arginine deiminase (ADI) has been found to be of significant clinical benefit in the treatment of hepatoceullar carcinomas (HCC), renal cell carcinomas and melanoms. However the therapeutic utility of bacterial ADI enzymes is severely compromised by its high immunogenicity. We propose to engineer human enzymes that exhibit optimal catalytic, physical and pharmacokinetic properties without eliciting adverse immune responses. Combinatorial structure guided saturation mutagenesis, together with high throughput screening for arginine deiminase will be employed to generate two candidate enzymes: (i) mutants of peptidyl arginine deiminase 4 that hydrolyze L-Arginine instead of peptidyl arginine with high activity and (ii) engineered human Arginase variants exhibiting >10-fold lower KM for L-Arginine in plasma. The cytotoxic effect of these enzymes on various human HCC cell lines will be evaluated. Novel approaches for the modification of the engineered enzymes to achieved long serum persistence are described and these will be evaluated in mice. Finally, optimal dosing to achieve sustained depletion will be determined and tumor reduction and survival following administration will be assessed in human HCC xenografts. PUBLIC HEALTH RELEVANCE: Hepatocellular carcinomas (HCC) kill hundreds of thousands of people worldwide every year. These cancers are very aggressive, and very difficult to treat, making new treatments of the utmost importance. However, one new treatment approach has recently been found that promises to keep these killers at bay. Hepatocellular carcinomas have lost the ability to make the amino acid L-Arginine, one of the building blocks necessary for cell growth. Cancer cells cope with this by scavenging L-Arginine from their surroundings and continue with unchecked growth. Excitingly though, when these tumors are treated with a bacterial enzyme that breaks down L-Arginine, these cancers starve to death while normal tissue is unharmed. The downside is that the body's immune system violently reacts to foreign particles, often making the treatment as dangerous as the disease. Our goal is take human enzymes and "tweak" them slightly so that they will efficiently break down L-Arginine. Dangerous immune responses will be avoided because these enzymes will be recognized as normal human proteins. In this proposal we will continue the engineering of two human enzymes (Peptidylarginine Deiminase and Arginase) that have already led to significant improvements in therapeutic potential. Using standard protein engineering techniques we will make highly active, and stable enzymes that will enable cancer cells to be specifically eliminated, without the harmful side-effects from using bacterial proteins. We believe that the research outlined here can create safe, effective, therapeutic agents for patients with hepatocellular carcinomas, and give our afflicted loved ones a second chance at life.

描述（由申请人提供）：该提案的总体目标是利用蛋白质工程的现代技术来开发新一代的非免疫原性和药理学优化的酶，以通过全身性L-精氨酸消耗来化疗肝癌和黑色素瘤的化学疗法。已经发现，使用卵巢细菌精氨酸脱节酶（ADI）对精氨酸的酶促耗竭在治疗肝癌癌（HCC），肾细胞癌和黑色素方面具有重要的临床益处。然而，细菌ADI酶的治疗效用受到其高免疫原性的严重损害。我们建议设计出具有最佳催化，物理和药代动力学特性的人类酶，而不会引起不良免疫反应。联合结构引导的饱和诱变以及精氨酸脱节酶的高吞吐量筛选将生成两种候选酶：（i）肽基精氨酸脱氨酶4的突变体，该突变体将L-精氨酸水解L-精氨酸而不是肽基精氨酸而不是具有高活性和（II）较高的人精氨酸酶较低的km for loldme km。这些酶对各种人HCC细胞系的细胞毒性作用将得到评估。描述了修饰工程酶以实现长血清持久性的新方法，并将在小鼠中进行评估。最后，将确定达到持续耗竭的最佳剂量，并将在人类HCC异种移植物中评估肿瘤减少和肿瘤的生存。公共卫生相关性：肝细胞癌（HCC）每年杀死数十万人。这些癌症非常激进，很难治疗，这是最重要的新疗法。但是，最近发现了一种新的治疗方法，该方法有望使这些杀手陷入困境。肝细胞癌失去了使氨基酸L-精氨酸的能力，L-精氨酸是细胞生长所必需的基础之一。癌细胞通过从周围的环境中清除L-精氨酸来应对这一点，并继续未经检查的生长。令人兴奋的是，当这些肿瘤用细菌酶分解L-精氨酸治疗时，这些癌症在正常组织没有受伤的同时饿死。不利的一面是，人体的免疫系统对外国颗粒产生了剧烈反应，通常使治疗与疾病一样危险。我们的目标是服用人类酶，并稍微“调整”它们，以便有效地分解L-精氨酸。将避免使用危险的免疫反应，因为这些酶将被识别为正常的人蛋白。在此提案中，我们将继续进行两种人类酶（肽基金氨酸脱氨酸酶和精氨酸酶）的工程，这些酶已经导致了治疗潜力的显着改善。使用标准蛋白质工程技术，我们将制造高度活跃和稳定的酶，这些酶将能够特异性消除癌细胞，而不会使用细菌蛋白产生有害的副作用。我们认为，这里概述的研究可以为患有肝细胞癌的患者创造安全，有效，治疗剂，并给我们受苦的亲人带来第二次生命机会。

项目成果

期刊论文数量（8）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（10）

The second-shell metal ligands of human arginase affect coordination of the nucleophile and substrate.

人精氨酸酶的第二壳金属配体影响亲核试剂和底物的配位。

DOI：
10.1021/bi101542t
发表时间：
2010
期刊：
Biochemistry
影响因子：
2.9
作者：
Stone,EverettM;Chantranupong,Lynne;Georgiou,George
通讯作者：
Georgiou,George

Uncoupling intramolecular processing and substrate hydrolysis in the N-terminal nucleophile hydrolase hASRGL1 by circular permutation.

DOI：
10.1021/cb300232n
发表时间：
2012-11-16
期刊：
ACS CHEMICAL BIOLOGY
影响因子：
4
作者：
Li, Wenzong;Cantor, Jason R.;Yogesha, S. D.;Yang, Shirley;Chantranupong, Lynne;Liu, June Qingxia;Agnello, Giulia;Georgiou, George;Stone, Everett M.;Zhang, Yan
通讯作者：
Zhang, Yan

De novo engineering of a human cystathionine-ýý-lyase for systemic (L)-Methionine depletion cancer therapy.

用于全身（L）-甲硫氨酸耗竭癌症治疗的人胱硫醚-α-裂解酶的从头工程。

DOI：
10.1021/cb300335j
发表时间：
2012
期刊：
ACS chemical biology
影响因子：
4
作者：
Stone,Everett;Paley,Olga;Hu,Jian;Ekerdt,Barbara;Cheung,Nai-Kong;Georgiou,George
通讯作者：
Georgiou,George

The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity.